CCM
ALNY icon

Capstone Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capstone Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Sell
1,057
-710
-40% -$214K 0.14% 147
2026
Q1 		$585K Sell
1,767
-534
-23% -$182K 0.59% 34
2025
Q4 		$915K Buy
+2,301
New +$1.02M 0.88% 36

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Capital Management's ALNY Position: Q2 2026 in Review

Capstone Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 40% in Q2 2026, selling an estimated $214K and leaving 1,057 shares worth $318K. The position accounts for 0.14% of the portfolio, ranked #147.

Capstone Capital Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $915K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Capstone Capital Management held 1,057 shares of Alnylam Pharmaceuticals worth $318K as of Q2 2026.
  • Capstone Capital Management sold 710 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $214K.
  • Alnylam Pharmaceuticals made up 0.14% of Capstone Capital Management's portfolio in Q2 2026, its #147 holding.
  • Capstone Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Capstone Capital Management's Alnylam Pharmaceuticals position peaked at $915K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Capstone Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.